期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性白血病患者外周血几种细胞因子水平的测定及其意义 被引量：2

IN VITRO THE EFFECT OF IL 3,G CSF AND GM CSF ON CYTOTOXICITY OF ARA C
下载PDF
导出
摘要 目的了解ＩＬ－２等细胞因子在白血病发病机制中的作用。方法测定了５１例急性白血病患者ＰＢＭＮＣ培养上清中ＩＬ－２、ＩＬ－６水平及血清ｓＩＬ－２Ｒ、ＴＮＦα水平。结果（１）急性白血病患者ＰＢＭＮＣ培养上清的ＩＬ－２水平显著低于正常（Ｐ＜０．０１）及ＣＲ组（Ｐ＜０．０５）；而ＩＬ－６水平显著高于正常及ＣＲ组（Ｐ＜０．０１）。（２）急性白血病患者血清ｓＩＬ－２Ｒ及ＴＮＦα水平显著高于正常及ＣＲ组（Ｐ＜０．０１）。（３）急性白血病患者血清ｓＩＬ－２Ｒ水平与其外周血幼稚细胞比例呈正相关（ｒ＝０．４１０，Ｐ＜０．０５）；在Ｍ５患者中血清ｓＩＬ－２Ｒ与ＴＮＦα水平正相关（ｒ＝０．８７４，Ｐ＜０．０１）。结论急性白血病患者存在着细胞因子网络的失调，并在急性白血病的发生、发展中起一定的作用。 Objective Recombinant human hematopoietic growth factor (rhHGF) and chemotherapeutic drugs combined treatment is a new strategy which may be useful cure for acute myeloid leukemia. MethodsThe sensitivity of Ara C to mononuclear cell with acute leukemia was detected by INT.Results The results suggested enhancement of the cytotoxicity of Ara C by G CSF、IL 3 or GM CSF.However,none of the HGF significantly affected the drugs cytotoxicity of MNC. The different effects of rhHGF on the sensitivity of the chemotherapeutic drugs in normal versus leukemic cells. Conclusion rhHGF combined with chemotherapeutic drugs may indicate a role for rhHGF in enhancing the selectivity of drugs toward leukemic myeloblasts.
作者 秦平 王学永
机构地区 山东医科大学附属医院
出处 《白血病》 1999年第2期94-96,共3页
关键词 急性 白血病 白细胞介素 肿瘤坏死因子 Hematopoietec growth factor Acute myeloid leukemia Cytosine arabinoside
分类号 R733.710.2 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献2

  • 1任红，中国免疫学杂志，1992年，8卷，45页
  • 2Lang R A，Immuncl Today，1990年，11卷，244页

共引文献4

同被引文献15

  • 1Halak B K, Maguire H C, Lattime E C. Tumor-induced interleulin-10 inhibits type 1 immune responsesdirected at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res, 1999, 59:911-917.
  • 2Hsieh C L, Chen D S, Hwang L H, et al. Tumor-induced immunosuppression., a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine.Human Gene Therapy,2000,11:681-692.
  • 3Yotnda P, Mintz P, Grigoriadou K, et al. Analysis of T-cell defects in the specific immunc response against acute lymphoblastic leukemia cells. Experimental Hematology, 1999, 27 :1375-1383.
  • 4Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment Protects target cells from tumor and allo - specific cytotoxic T cells and downregulates HLA class I expression[J]. J Exp Med, 1994,180:2371- 2376.
  • 5Hsieh CL, Chen DS, Hwang LH, et al.Tumor- induced immunosupp-ression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine[ J]. Human Gene Therapy,2000,11:681 - 692.
  • 6Groux H, Bigler M, Devries JE, et al. Interleukin - 10 induces a long -term aritigen- specific anergic state in human CD4^+ T cells[J]. J Exp Med, 1996,184:19-25.
  • 7Yothda P, Mintz P, Grigoriadou K, et al. Analysis of T-cell defects in the specifie immune response against acute lymphoblastic leukemia cells[J]. Experimental Hematology, 1999,27:1375 - 1383.
  • 8Zou JP, Yamamoto N, Fujii T, et al. Systemic administration of rIL - 12 induces complete tumor regression and protective immunity: response in correlated with a striking reversal of suppressed IFN - gamma production by anti - tumor- T cells[J]. Int Immunol, 1995,7:1135 - 1138.
  • 9Dunusai - Joannopoulos K, Runyon K, Erickson J, et al. Vaccines with interleukin - 12 - transdued acute myeloid leukemia cells elicit very potent therapeutic and long- lasting protective immunity[J]. Blood, 1999, 94(2) :4263 - 4273.
  • 10Deeths M J, Mescher MF. ICAM - 1 and B 7 - 1 provide similar but distinct costimulaiton for CD8^+ T cells, while CD4^+ T cells are poorly costimulated by ICAM- 1[J].Eur J Immunol, 1999,29:45 - 49.

引证文献2

二级引证文献8

白血病
1999年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部